Disulfide Bond-Based SN38 Prodrug Nanoassemblies with High Drug Loading and Reduction-Triggered Drug Release for Pancreatic Cancer Therapy.

Zhong, Zhi-Xin; Li, Xu-Zhao; Liu, Jin-Tao; Qin, Nan; Duan, Hong-Quan; Duan, Xiao-Chuan

Zhong, Zhi-Xin; Li, Xu-Zhao; Liu, Jin-Tao; Qin, Nan; Duan, Hong-Quan; Duan, Xiao-Chuan.

Afiliação

Zhong ZX; School of Pharmacy, Tianjin Medical University, Tianjin, 300070, People's Republic of China.
Li XZ; School of Pharmacy, Tianjin Medical University, Tianjin, 300070, People's Republic of China.
Liu JT; School of Pharmacy, Tianjin Medical University, Tianjin, 300070, People's Republic of China.
Qin N; School of Pharmacy, Tianjin Medical University, Tianjin, 300070, People's Republic of China.
Duan HQ; School of Pharmacy, Tianjin Medical University, Tianjin, 300070, People's Republic of China.
Duan XC; Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, People's Republic of China.

Int J Nanomedicine ; 18: 1281-1298, 2023.

Article em En | MEDLINE | ID: mdl-36945256

Assuntos

Nanopartículas; Neoplasias Pancreáticas; Pró-Fármacos; Humanos; Pró-Fármacos/química; Liberação Controlada de Fármacos; Irinotecano/farmacologia; Sistemas de Liberação de Medicamentos/métodos; Neoplasias Pancreáticas/tratamento farmacológico; Dissulfetos/química; Linhagem Celular Tumoral; Nanopartículas/química; Camptotecina; Neoplasias Pancreáticas

Palavras-chave

7-ethyl-10-hydroxycamptothecin; glutathione responsive; nanoassemblies; pancreatic cancer therapy; prodrug

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Pró-Fármacos / Nanopartículas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google